CHIA BIO / REGENERATIVE MEDICINE
IN PRECLINICAL DEVELOPMENTA full head of hair.Still out of reach
for millions.
Chia Bio is working to change that.
Limited donor hair can make transplantation unsuitable.
Illustrative portraitsFor many people with advanced hair loss or diffuse thinning, today’s treatments fall short of the coverage they want. We’re developing a new source of hair follicles from their own cells.
YOUR CELLS.
NEW HAIR FOLLICLES.
A NEW POSSIBILITY.
01 / THE OPPORTUNITY
Hair restoration has
a supply problem.
A transplant can move hair.
Our goal is to make more.
Hair transplantation relies on a finite supply of donor follicles. For people with advanced loss or diffuse thinning, that supply can limit what’s possible.
We’re working toward a different starting point: new follicles grown from a patient’s own cells, designed for use in the transplant workflow surgeons already know.
See how we’re approaching itCHIA BIO / THE REGENERATIVE JOURNEY
Intended treatment concept · Preclinical developmentYour cells.
A whole new possibility.
Follow the science from a blood-derived cell
to the possibility of new, patient-derived hair.
A small sample.
Extraordinary potential.
A nucleated cell from a routine blood sample provides the starting point for a new source of patient-derived hair follicles.
A vision of what may become possible. This sequence illustrates an intended treatment concept. Chia Bio is in preclinical development; human safety and efficacy remain to be established. All images are conceptual renderings. The hair outcome is illustrative.
03 / THE SCIENTIFIC FOUNDATION
New growth begins
with new biology.
Our approach builds on published research showing that human pluripotent stem cells can form hair-bearing skin organoids: small, three-dimensional tissues that develop features of human skin.
These studies demonstrated hair follicle formation in the lab and hair-bearing grafts in mouse models. We’re working to translate that foundation into a patient-derived approach to hair restoration.
Human safety and efficacy have not yet been established. Chia Bio’s technology is not available as a treatment.
PUBLISHED PRECLINICAL PROOF OF CONCEPT
Human hair growth.
Demonstrated in vivo.
Published research demonstrated hair-bearing human skin organoid grafts after transplantation into mice. This work provides a preclinical foundation for Chia Bio’s approach.
Read the published study (opens in a new tab)
04 / OUR VISION
Regenerative medicine.
Starting with hair.
The potential of cell replacement.
The personal meaning of hair.
We believe hair restoration can become an important application of regenerative medicine: one that brings together stem cell science, manufacturing, and an established clinical workflow.
Our ambition is to expand access to new follicles and, over time, help make patient-derived cell replacement more scalable.
A FEW COMMON QUESTIONS
A clearer picture.
How is this different from a hair transplant?
A conventional transplant redistributes existing follicles from a donor area. Chia Bio is developing a way to grow new follicles from a patient’s own cells, with the aim of supplying them for implantation.
What does “patient-derived” mean?
It means the starting cells come from the person who would ultimately receive the follicles. This is also called an autologous approach.
Is Chia Bio offering treatment or enrolling patients?
No. Our technology is in preclinical development and is not available as a treatment. Human safety and efficacy remain to be established. We are not accepting treatment bookings or patient enrollment through this website.
Who would you like to hear from?
We welcome conversations with investors, scientific collaborators, manufacturing partners, and hair restoration clinicians. Please reach us at contact@chia.bio.
LET’S BUILD WHAT COMES NEXT